xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorJustino, Maria Cleonice Aguiar-
dc.contributor.authorLinhares, Alexandre da Costa-
dc.contributor.authorLanzieri, Tatiana. M-
dc.contributor.authorMiranda, Ylle-
dc.contributor.authorMascarenhas, Joana D'Arc Pereira-
dc.contributor.authorAbreu, Erika-
dc.contributor.authorGuerra, Sylvia de Fátima dos Santos-
dc.contributor.authorOliveira, Alessilva S. L-
dc.contributor.authorSilva, Veronice B da-
dc.contributor.authorSanchez, Nervo-
dc.contributor.authorMeyer, Nadia-
dc.contributor.authorShafi, Fakrudeen-
dc.contributor.authorOrtega-Barria, Eduardo-
dc.contributor.authorSoriano-Gabarró, Montse-
dc.contributor.authorColindres, Romulo E-
dc.date.accessioned2016-01-26T11:39:50Z-
dc.date.available2016-01-26T11:39:50Z-
dc.date.issued2011-
dc.identifier.citationJUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011pt_BR
dc.identifier.issn1871-0336-
dc.identifier.urihttp://patua.iec.gov.br/handle/iec/946-
dc.description.abstractBackground: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.pt_BR
dc.format.mimetypeapplication/pdf-
dc.language.isoengpt_BR
dc.publisherLippincott, Williams & Wilkinspt_BR
dc.rightsAcesso Abertopt_BR
dc.titleEffectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazilpt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryGastroenterite / virologiapt_BR
dc.subject.decsPrimaryRotavirus / isolamento & purificaçãopt_BR
dc.subject.decsPrimaryVacinas contra Rotaviruspt_BR
dc.subject.decsPrimaryHospitalizaçãopt_BR
dc.coverage.temporalragefrom2008-
dc.coverage.temporalrageupto2009-
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals. Wavre, Belgium.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals. Bangalore, India.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals, Wavre, Belgium.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brasilpt_BR
dc.identifier.doi10.1097/INF.0b013e3182055cc2-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple